Abstract: For magnetic resonance (MR) reconstruction using artificial intelligence (AI), the AI-based reconstruction for MR imaging systems is offloaded to one or more servers. A remote server performs AI-based reconstruction. A library of recent, old, custom, and/or publicly available AI-based reconstruction processes may be rapidly deployed and available to the server, which has the memory and processing resources for AI-based reconstruction. Load balancing of the data and/or between servers may improve performance.

Abstract: A method, apparatus and non-transitory computer readable medium are for segmenting different types of structures, including cancerous lesions and regular structures like vessels and skin, in a digital breast tomosynthesis (DBT) volume. In an embodiment, the method includes: pre-classification of the DBT volume in dense and fatty tissue and based on the result; localizing a set of structures in the DBT volume by using a multi-stream deep convolutional neural network; and segmenting the localized structures by calculating a probability for belonging to a specific type of structure for each voxel in the DBT volume by using a deep convolutional neural network for providing a three-dimensional probabilistic map.

Abstract: The invention relates to pyridazinone and pyridone compounds having formula (I) or (I?), and pharmaceutically acceptable salts, hydrates, and solvates thereof wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: A method, apparatus and non-transitory computer readable medium are for segmenting different types of structures, including cancerous lesions and regular structures like vessels and skin, in a digital breast tomosynthesis (DBT) volume. In an embodiment, the method includes: pre-classification of the DBT volume in dense and fatty tissue and based on the result; localizing a set of structures in the DBT volume by using a multi-stream deep convolutional neural network; and segmenting the localized structures by calculating a probability for belonging to a specific type of structure for each voxel in the DBT volume by using a deep convolutional neural network for providing a three-dimensional probabilistic map.

Abstract: A computer-implemented method for reconstructing magnetic resonance images using a parallel computing platform comprising a host unit and a graphical processing device includes receiving a plurality of coil data sets from a magnetic resonance imaging system, each respective coil data set comprising scanner data and a coil sensitivity map associated with a distinct coil included in the magnetic resonance imaging system. An iterative compressed-sensing reconstruction process is applied to reconstruct an image based on the plurality of coil data sets.

Abstract: The invention relates to pyridazinone and pyridone compounds having formula (I) or (I?), and pharmaceutically acceptable salts, hydrates, and solvates thereof wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: The invention relates to pyridazinone and pyridone compounds having formula (I) or (I?), and pharmaceutically acceptable salts, hydrates, and solvates thereof wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: The invention relates to pyridazinone and pyridone compounds having formula (I) or (I?), and pharmaceutically acceptable salts, hydrates, and solvates thereof wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: A computer-implemented method for reconstructing magnetic resonance images using a parallel computing platform comprising a host unit and a graphical processing device includes receiving a plurality of coil data sets from a magnetic resonance imaging system, each respective coil data set comprising scanner data and a coil sensitivity map associated with a distinct coil included in the magnetic resonance imaging system. An iterative compressed-sensing reconstruction process is applied to reconstruct an image based on the plurality of coil data sets.

Abstract: The invention relates to pyridazinone and pyridone compounds having formula (I) or (I?), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: The invention relates to pyridazinone and pyridone compounds having formula (I) or (I?), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The novel compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof wherein R1 to R11 are as defined herein.

Abstract: The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases.

Abstract: The present invention is directed to hydrazono compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases.

Abstract: The present invention is directed to hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R1 to R8 and X are as defined herein.

Abstract: The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases.

Abstract: New compounds with the ability to inhibit calcium uptake in the brains of mammals are disclosed of the Formula (I) ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 to C.sub.4 alkyl, phenyl, or phenyl-C.sub.1 to C.sub.4 alkyl;one of R.sup.2 and R.sup.3 is C.sub.1 to C.sub.4 alkoxy and the other one is phenyl-C.sub.1 to C.sub.4 alkoxy optionally substituted by C.sub.1 to C.sub.4 alkyl in the aromatic nucleus; andR.sup.4 is phenyl optionally substituted by C.sub.1 to C.sub.4 alkyl in the aromatic nucleus, or their solvates, individual optically active and geometric isomers, mixtures of such isomers, as well as pharmaceutically acceptable acid addition salts thereof. The compounds of the Formula (I) are capable of inhibiting calcium uptake to brain cells and have a protective effect on hypobaric hypoxia.

Abstract: A silicon rubber embolization agent used in general as well as cerebral vascular surgery having a component A which is composed of: a linear, low viscosity polysiloxane selected from the group consisting of dialkyl, alkylaryl, alkenylalkyl, and diarylpolysiloxanes having reactive functional groups selected from the group consisting of hydroxyl, acyloxyl, alkoxyl and amino; a low viscosity cyclic dialkylpolysiloxane having the formula [R.sub.2 SiO].sub.4, wherein R is alkyl; a pharmaceutically acceptable iodo-containing organosilicium; or a non-metallic, organic X-ray contrast material, and a component B which is a therapeutically acceptable cross-linking catalyst.

Abstract: A therapeutic set or kit containing a silicon rubber mixture for surgical embolization composed of(a) a linear, low viscosity polysiloxane selected from the group consisting of dialkyl, alkylaryl, alkenylalkyl, and diaryl polysiloxanes having reactive functional groups selected from the group consisting of hydroxy, acyloxy, alkoxy and amino;(b) a cyclic dialkyl polysiloxane having the formula [R.sub.2 SiO].sub.4, wherein R is alkyl; anda pharmaceutically acceptable iodo-containing organosilicium X-ray contrast material or non-metallic organic X-ray contrast material. The mixture can be used in cerebrovascular surgery and general surgery for surgical embolization with the aid of a catheter.

Abstract: A silicon rubber mixture for surgical embolization composed of(a) a linear, low viscosity polysiloxane selected from the group consisting of dialkyl, alkylaryl, alkenylalkyl, and diaryl polysiloxanes having reactive functional groups selected from the group consisting of hydroxy, acyloxy, alkoxy and amino;(b) a cyclic dialkyl polysiloxane having the formula [R.sub.2 SiO].sub.4, wherein R is alkyl; anda pharmaceutically acceptable iodo-containing organosilicium X-ray contrast material or non-metallic organic X-ray contrast material. The mixture can be used in cerebrovascular surgery and general surgery for sugical embolization with the aid of a catheter.